The tool's developer, LIV Process, says it has created a water-based reagent that illuminates Clostridioides difficile on surfaces so teams can verify cleaning in real time.

Rachel Britt, PharmD, BCIDP, provides insights around an evolving understanding of the long-time antibiotic’s limitations for these infections, provides guidance on other agents, and the role of diagnostics in finding the best agents for patients. #IDsky #Medsky

Immunocore’s first-in-human study of its bispecific, IMC-I109V, demonstrated early antiviral activity and a favorable safety profile, supporting continued development of the TCR bispecific candidate as a potential functional cure for chronic hepatitis B.

In Vir Biotechnology’s phase 2 Solstice study, 66% of participants with chronic hepatitis delta (CHD) receiving a monthly dose of combination tobevibart and elebsiran achieved undetectable hepatitis delta virus (HDV) RNA at Week 48.

Seven months of clinical data corroborated emergency authorization of 2024-2025 mRNA COVID-19 vaccines for circulating JN1 subvariants. #IDsky #Medsky

RSV vaccines protected older adults against RSV-related hospitalization over 2 seasons, although with less effectiveness for those with immunocompromise or cardiovascular disease. #IDsky #Medsky

Penicillin-binding proteins are dynamic, multifunctional regulators of bacterial cell-wall construction whose shifting behaviors under different biological conditions shape β-lactam activity, tolerance, and resistance Learn more in this @sidpharm.bsky.social column.

This week, read about the FDA's approval of IV antibiotic, Contepo, for complicated urinary tract infections, penicillin‑binding proteins, post-exposure doxycycline for Lyme disease prevention in young children, and more. #IDsky #Medsky

In the latest Bench to Bedside column from the @sidpharm.bsky.social, the authors discuss how PBPs are more than static β lactam targets. Host conditions rewire PBP activity and peptidoglycan architecture, shaping tolerance, resistance, and how we design salvage regimens. #IDsky #Medsky

Wesley Kufel, Pharm.D, BCPS, BCIDP, FCCP, FIDSA, points out many clinicians are unaware of this. He also discusses its efficacy at preventing the disease. #IDsky #Medsky

Dynavax and Vaxart have entered into a license and collaboration agreement to advance Vaxart’s investigational oral COVID-19 vaccine, with phase 2b data expected in late 2026. #IDsky #Medsky

IND clearance enables a randomized, double-blind study of IMM-529 with standard care, while a forthcoming USU Travelan field readout will guide dosing strategy. #IDsky #Medsky

#ICYMI The federal agency gave the nod to Meitheal Pharmaceuticals for its antibiotic, Contepo, an intravenous fosfomycin offering a new mechanism of action and a new option for adults with complicated urinary tract infections, including those caused by resistant Gram-negative pathogens. #IDsky

In a multinational NEJM trial, a single 105 mg dose cut RSV hospitalizations by 84.2% and medically attended lower respiratory infection by 60.4% through 150 days, with safety similar to placebo. #IDsky #Medsky

The Centers for Disease Control and Prevention (CDC) provided more information on a multistate outbreak. www.contagionlive.com/view/listeri...

#Breaking FDA gave the nod to Meitheal Pharmaceuticals for its antibiotic, Contepo, an intravenous fosfomycin offering a new mechanism of action and a promising option for adults with complicated urinary tract infections. #IDsky #Medsky

A survey taken this past summer shows immunization confidence waning. Dr. Ruth Lynfield discusses an approach clinicians can take in counseling parents who may have concerns about the vaccine and other strategies to increase immunization adherence. #IDsky #Medsky

Anne Kasmar, MD, MSc, highlighted how expanding beyond traditional antibiotics, strengthening regulatory partnerships, and leveraging immunology are accelerating the next generation of antimicrobial resistance (AMR) solutions. #IDsky #Medsky

The foundation has unveiled its 2025 campaign, highlighting the deadly toll and long-term consequences of these infections through nationwide events, education initiatives, and tributes throughout November. #IDsky #Medsky

Prescribing of antiviral medication for children at risk of severe influenza decreased in COVID-19 pandemic despite unchanged treatment guidelines. #Idsky #Medsky

This week review more highlights from IDWeek, and why one researcher is predicting a milder avian influenza season. #IDsky #Medsky

Richard Webby, PhD, says increased wild bird immunity is a major factor for this year’s prediction. #IDsky #Medsky @stjuderesearch.bsky.social

Muhammad Sohaib Asghar, MBBS, MD, discusses why CDI deaths are concentrated in White patients and inpatient/long-term care settings, why mortality peaked in 2006–2015, and how stewardship and recurrence prevention are driving the recent decline. #IDsky #Medsky

In his new position, Gareth Morgan, MS, MBA, provides insights on antibiotic development strategies he would like to see during his tenure.

Bird migration has started. Surveillance and early detection are key, especially as it relates to H5N1 and predicting this year's respiratory virus season. #IDsky #Medsky

Jill Blumenthal, MD, MAS, offers some insights on the results from a subset of Gilead’s phase 3 PURPOSE 2 study. #IDsky #Medsky

The XpertHCV test from Cepheid enables rapid, point-of-care detection of hepatitis C infection in under an hour—helping to expand access to care and reduces follow-up loss. #IDsky #Medsky

At IDWeek, Jean van Wyk, MBChB, MFPM, chief medical officer, ViiV Healthcare, discussed the 96-week results from the PASO DOBLE study and the preliminary long-acting injectable PrEP results from the CLARITY study. #IDsky #Medsky

Ashlan Kunz Coyne, PharmD, MPH, discusses the potential of combining antibiotics with phage cocktail therapy in treating these types of infections.

Sustained HIV/syphilis elimination of mother-to-child transmission (EMTCT) since 2019 and new hepatitis B validation reflect high antenatal screening, >95% HBV birth-dose coverage, and integrated maternal–child health services. #IDsky #Medsky www.contagionlive.com/view/maldive...

This is part 2 of 2-part coverage of the WHO Global Antibiotic Resistance Surveillance System Report 2025. #IDsky #Medsky

Here is part 1 of 2-part coverage of the WHO Global Antibiotic Resistance Surveillance Report. #IDsky #Medsky

This week, meet SIDP's president-elect, the connection between UTIs and meat, a COVID-19 vaccine alternative, and other highlights from IDWeek. #IDWeek2025 #IDsky www.contagionlive.com/view/top-inf...

A new genomic study reveals that up to 18% of urinary tract infections (UTIs) in Southern California may stem from E coli strains transmitted through contaminated poultry and meat.#IDsky

Jesse Clark, MD, MSc, discusses a study’s subset preliminary findings looking at this form of PrEP in this patient population. #IDWeek2025 #IDsky

Ed J Kuijper, MD, PhD details who is at highest risk for rCDI, how to interpret NAAT–toxin results, and how to sequence fidaxomicin, vancomycin, and microbiota-based therapies. #IDsky #Medsky

Moderna’s investigational cytomegalovirus (CMV) vaccine, mRNA-1647, did not meet its primary endpoint in a phase 3 trial, leading the company to discontinue its congenital CMV program while continuing studies in transplant patients.

Dr. Lisa Dumkow discusses her goals for her tenure as well as professional societies' roles in public health advocacy and AI. #IDWeek2025 @sidpharm.bsky.social www.contagionlive.com/view/meet-si...

At IDWeek, the company reported promising phase 1/2 trial results for its shingles vaccine candidate Z-1018, demonstrating strong immune responses and favorable tolerability. #IDWeek2025 #IDsky

Phase 3 results for tebipenem HBr suggest an oral carbapenem could provide an effective alternative to IV therapy for multidrug-resistant UTIs. #IDWeek2025 #IDsky

Cornelius Clancy, MD, discusses insights from the real-world clinical analysis of the US cohort of the PROVE study. #IDWeek2025 #IDsky

Lori Handy, MD, MSCE, emphasized that rebuilding public trust requires continuous engagement and a collective rethinking of medical communication. #IDWeek

Researchers say affordable lenacapavir could transform global HIV prevention efforts amid rising infection rates.

Findings from the ongoing ROAR registry show that fecal microbiota, live-jslm (RBL), maintains strong efficacy and safety in preventing recurrent Clostridioides difficile infection (rCDI) in routine US clinical practice. #IDWeek2025 #IDsky

Day 2 at #IDWeek2025, come by to say hello to the Contagion Editorial team. We are right outside Room 316B conducting interviews. We hope to see you!

Invivyd’s Chief Scientific Officer Robert Allen, PhD, provides insights on the company's investigational monoclonal antibody, VYD2311, as well as its REVOLUTION clinical program. @invivyd.bsky.social #IDWeek2025 #IDWeek #IDsky

Nicholas Marshall, MD, FAAP, discussed how generative AI can help streamline infectious disease workflows and enhance evidence-based care at #IDWeek2025 in Atlanta. #IDsky

IDWeek Chair, Infectious Diseases Society of America, Yohei Doi, MD, provides some insights on the happenings at this year’s event. #IDWeek2025

Dr Lori Handy from Children's Hospital of Philadelphia stopped by to talk about vaccine education and communication and she picked up our pseudomonas plushie! #IDWeek2025

Come see the Contagion editors at #IDWeek2025 outside room 316B!